ÂÜÀòÂÒÂ×

Mark Pruzanski, MA, MD, currently serves as Chairman of the Board at Corteria Pharmaceuticals and Abcuro, Inc., as well as Biotechnology Executive at FIGURATI LLC. Pruzanski has been a Board Member at eGenesis, Inc., Equillium, Inc., and the Biotechnology Innovation Organization since 2021, 2018, and 2011 respectively, and has been on the Board of the Foundation for Defense of Democracies since 2005. As the founder and former CEO of Intercept Pharmaceuticals, Pruzanski played a pivotal role until November 2023. Additional leadership experience includes serving as CEO of Versanis Bio, which was acquired by Eli Lilly and Company in August 2023. Pruzanski holds an MD from McMaster University Medical School, an MA from Johns Hopkins SAIS, and a BA from McGill University.